



acknowledged in the specification, page 2, that mono- or di-aminopyridines are known to improve nerve conduction in diseases such as multiple sclerosis and Alzheimer's. What is not known or suggested in the prior art is the method for administering a sustained release formulation of mono- or di-aminopyridines at a rate allowing controlled absorption over a not less than a twelve hour period where the levels of active ingredient achieved *in vivo* are therapeutically effective over the 12-24 hour periods following administration. Claim 38 has been amended to reflect these distinguishing features.

In response to the Notice of Draftsperson's Patent Drawing Review wherein the drawings are objected to under paragraph 10, i.e. the lines, numbers and letters are not uniformly thick and well defined, submitted herewith are corrected drawings to overcome this objection.

Based on the above, it is respectfully submitted that the above-referenced application is now in condition for allowance and such action is earnestly solicited.

Should the Examiner believe that any further action is necessary in order to place the application in condition for allowance, he is encouraged to call the undersigned at the telephone number listed below.

Respectfully submitted,

Marla J. Church  
Attorney for Applicant  
Registration No. 29,908

ELAN PHARMACEUTICAL  
RESEARCH CORPORATION  
1300 Gould Drive  
Gainesville, GA 30504  
Telephone: (404) 534-8239

L:\patent\1806\res-7-20.doc

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on this 20th day of July, 1995.

Donna Jackson

7-20-95  
Date